tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Schwartz JJ et al. | Decreased incidence of acute rejection in adolescent kidney transplant recipients using antithymocyte induction and triple immunosuppression. | 2007 | Transplantation | pmid:17893604 |
| Tydén G et al. | Implementation of a Protocol for ABO-incompatible kidney transplantation--a three-center experience with 60 consecutive transplantations. | 2007 | Transplantation | pmid:17496528 |
| Pescovitz MD et al. | Prospective observational study of sirolimus as primary immunosuppression after renal transplantation. | 2009 | Transplantation | pmid:19855247 |
| Miroux C et al. | In vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function. | 2012 | Transplantation | pmid:22743548 |
| Lenaers JI et al. | Relevance of posttransplant flow cytometric T- and B-cell crossmatches in tacrolimus-treated renal transplant patients. | 2006 | Transplantation | pmid:17102764 |
| Atkison PR et al. | Arteritis and increased intracellular calcium as a possible mechanism for tacrolimus-related cardiac toxicity in a pediatric transplant recipient. | 1997 | Transplantation | pmid:9311719 |
| Gallon L et al. | ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients. | 2006 | Transplantation | pmid:16477235 |
| Sanchez EQ et al. | Predicting renal failure after liver transplantation from measured glomerular filtration rate: review of up to 15 years of follow-up. | 2010 | Transplantation | pmid:20098288 |
| Niioka T et al. | Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation. | 2012 | Transplantation | pmid:23073468 |
| Miyazawa H et al. | Hamster to rat kidney xenotransplantation. Effects of FK 506, cyclophosphamide, organ perfusion, and complement inhibition. | 1995 | Transplantation | pmid:7537396 |
| Fujii Y et al. | Effect of a novel immunosuppressive agent, FK506, on mitogen-induced inositol phospholipid degradation in rat thymocytes. | 1989 | Transplantation | pmid:2472025 |
| Calandra S | Sinus arrest during tacrolimus treatment: was the QT interval prolonged? | 1998 | Transplantation | pmid:9721813 |
| Aw MM et al. | Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience. | 2003 | Transplantation | pmid:12660504 |
| Lake JR et al. | The impact of immunosuppressive regimens on the cost of liver transplantation--results from the U.S. FK506 multicenter trial. | 1995 | Transplantation | pmid:7482713 |
| Kainz A et al. | Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. | 2000 | Transplantation | pmid:11152103 |
| Stephen M et al. | Immunosuppressive activity, lymphocyte subset analysis, and acute toxicity of FK-506 in the rat. A comparative and combination study with cyclosporine. | 1989 | Transplantation | pmid:2463701 |
| Opelz G and Döhler B | Association of mismatches for HLA-DR with incidence of posttransplant hip fracture in kidney transplant recipients. | 2011 | Transplantation | pmid:21452411 |
| Veenhof H et al. | Clinical Validation of Simultaneous Analysis of Tacrolimus, Cyclosporine A, and Creatinine in Dried Blood Spots in Kidney Transplant Patients. | 2017 | Transplantation | pmid:27906832 |
| MacPhee IA and Holt DW | A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype. | 2008 | Transplantation | pmid:18212618 |
| Tourret J et al. | Immunosuppressive Treatment Alters Secretion of Ileal Antimicrobial Peptides and Gut Microbiota, and Favors Subsequent Colonization by Uropathogenic Escherichia coli. | 2017 | Transplantation | pmid:27681266 |